CG Oncology, Inc. CGON
66.20 USD +2.14 (+3.34%)
Nov 4, 2026, 3:18 PM EST
63.16 Day range 66.42
35.80 52-week range 80.97
- YTD
- +59.44%
- 1 year
- +69.44%
Financial health
Altman Z-Score
60.02 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -20.0×
FY 2021 5y median -36.4× FY 2025
P/S 794×
FY 2021 5y median 1574× FY 2025
P/B 4.3×
FY 2021 5y median 13.4× FY 2025
P/FCF -24.2×
FY 2021 5y median -54.2× FY 2025
EV/EBITDA -20.0×
FY 2021 5y median -50.8× FY 2025
EV/Sales 788×
FY 2021 5y median 1348× FY 2025
FCF Yield -4.1%
FY 2021 5y median -1.8% FY 2025
Profitability
Gross Margin -15.0%
FY 2021 5y median -15.0% FY 2025
Operating Margin -4722.1%
FY 2021 5y median -10067.3% FY 2025
Net Margin -3985.0%
FY 2021 5y median -7729.5% FY 2025
ROE -21.4%
FY 2021 5y median -26.3% FY 2025
ROIC -25.0%
FY 2021 5y median -24.9% FY 2025
ROA -20.3%
FY 2021 5y median -21.9% FY 2025
Growth (YoY)
Revenue 254.7%
FY 2021 FY 2025
Operating Income -66.4%
FY 2021 FY 2025
EPS (diluted) -47.5%
FY 2021 FY 2025
Free Cash Flow -67.8%
FY 2021 FY 2025
Financial Health
Current Ratio 24.6×
FY 2021 5y median 13.6× FY 2025
Quick Ratio 24.6×
FY 2021 5y median 13.6× FY 2025
Debt / Equity 0.0×
FY 2021 5y median 0.0× FY 2025
Net Debt / EBITDA 0.2×
FY 2021 5y median 2.0× FY 2025
Interest Coverage 0.0×
FY 2021 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31